Physician

Juan Daniel Cuevas, MD

According to 2025 Medicare claims, Juan Cuevas, MD (NPI: 1295727493) practices hematology/oncology in the St. Louis, MO-IL market, with the plurality of this provider's patient population coming from St. Louis, MO. This provider's primary affiliated billing organization is ST. LOUIS CANCER CARE, L.L.P. (NPI: 1932156726; TIN: 431369550) and primary practice location at 63044-3432. Cuevas is affiliated with the SBL accountable care organization (ACO ID: A5147), participating under the MSSP model.

Cuevas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 235 traditional Medicare patients, billed 108,328 HCPCS/CPT codes, and received $3,332,486 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,491 prescription claims across 276 beneficiaries totaling $4,882,410 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 32 claims. Open Payments data shows 9 records totaling $13,954. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,203,326 to $3,332,486. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,654,409 to $4,882,410. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	456	212,232	$2,203,326
2016	444	178,980	$2,170,382
2017	447	119,084	$1,699,461
2018	468	93,799	$1,940,856
2019	470	130,985	$2,355,732
2020	384	108,169	$2,042,743
2021	371	81,668	$1,817,595
2022	323	116,112	$2,360,547
2023	281	138,431	$3,151,320
2024	235	108,328	$3,332,486

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	296	1,887	$1,654,409
2016	303	1,825	$1,778,999
2017	279	1,595	$2,127,147
2018	308	1,680	$2,443,824
2019	342	1,836	$4,321,395
2020	318	1,743	$4,568,827
2021	310	1,546	$4,594,889
2022	289	1,363	$3,884,182
2023	277	1,415	$3,345,884
2024	276	1,491	$4,882,410

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	258	$26,737
2016	N/R	172	$19,079
2017	N/R	12	$7,559
2018	N/R	69	$6,584
2019	N/R	142	$9,307
2020	N/R	149	$12,602
2021	N/R	45	$3,605
2022	N/R	11	$482
2023	N/R	32	$5,652
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	136	428	$101
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	81	108	$67
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	131	233	$13
36415	Insertion of needle into vein for collection of blood sample	133	385	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	151	728	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	52	1,449	$976,903
Calquence	Acalabrutinib Maleate	49	1,470	$666,328
Xtandi	Enzalutamide	37	1,110	$488,892
Imbruvica	Ibrutinib	17	476	$276,698
Lorbrena	Lorlatinib	12	360	$257,604

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$417	ASD Specialty Healthcare, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$13,537	Amgen Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Juan Daniel Cuevas, MD?

Tedicare shows public-source Medicare data for Juan Daniel Cuevas, MD (NPI 1295727493), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Juan Daniel Cuevas, MD have ACO affiliation data?

Juan Daniel Cuevas, MD is shown with ACO affiliation data for SBL accountable care organization (MSSP, ACO ID A5147).

What billing organization is linked to Juan Daniel Cuevas, MD?

Juan Daniel Cuevas, MD is linked to ST. LOUIS CANCER CARE, L.L.P. (billing NPI 1932156726) in the available physician profile data.

Does Juan Daniel Cuevas, MD have Open Payments data?

Juan Daniel Cuevas, MD has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.